OFS Credit (OCCI) Prices 1.03M Share Public Offering of Common Stock at $14.67/sh

OFS Credit Company, Inc. (the “Company”) (Nasdaq: OCCI, OCCIP) announced today that it has priced its previously announced underwritten public offering of shares of its common stock. The Company agreed to sell 1,025,000 shares of its common stock at a price to the public of $14.67 per share. In connection with the offering, the Company has granted the underwriters for the offering an option to purchase up to an additional 153,750 shares of the Company’s common stock to cover over-allotments, if any. The closing of the offering is subject to customary closing conditions and is expected to take place on March 30, 2021.

The Company expects to receive net proceeds from the offering, excluding the exercise of the over-allotment option, if any, of approximately $14,135,280, after deducting payment of underwriting discounts and estimated offering expenses payable by the Company. Assuming the full exercise of the over-allotment option, the net proceeds may reach approximately $16,300,572, after deducting payment of underwriting discounts and estimated offering expenses payable by the Company.

The Company intends to use the net proceeds of the offering to acquire investments in accordance with its investment objectives and strategies, to redeem all or a portion of its outstanding 6.875% Series A Term Preferred Stock due 2024 and/or 6.60% Series B Term Preferred Stock due 2023 and for general working capital purposes.

National Securities Corporation, B. Riley Securities, Inc. and Ladenburg Thalmann & Co. Inc. are acting as joint book-running managers for the offering. Maxim Group LLC and Aegis Capital Corp. are acting as lead managers for the offering. JonesTrading Institutional Services LLC is acting as co-manager for the offering.

You May Also Be Interested In

• Infinite Reality Acquires the Drone Racing League for $250 Million, Solidifying Position as Global Leader in Immersive Technology & Experiences (NBST)
• Akamai's (AKAM) API Security Product Achieves PCI Compliance and Sees Tremendous Customer Growth
• Incyte (INCY) Announces Acquisition of Escient Pharmaceuticals